Drug Discovery Online featured Jason Kirby, Chief Medical Officer at Recovery Centers of America, in a deeply reported thought-leadership piece examining what the growing body of GLP-1 receptor agonist research means for addiction medicine — and where the science still has work to do.
Kirby outlines how GLP-1R agonists, originally developed for metabolic conditions, have surfaced an unexpected connection to the brain’s reward circuitry. The piece interrogates the mechanism rigorously — from receptor distribution in mesocorticolimbic structures to the clinical translation challenges that early trial data have already exposed. His core argument: the signal is real, but it does not justify shortcuts in development.
The article is notable for what it doesn’t do. Rather than amplifying the hype around GLP-1s as a potential addiction breakthrough, Kirby methodically maps the gaps — metabolic confounds, species-specific expression differences, endpoint heterogeneity — and lays out what a disciplined development strategy actually requires. It’s the kind of clinical leadership voice the field needs more of.
For Recovery Centers of America, a byline of this caliber in a drug discovery publication reinforces the organization’s position at the forefront of evidence-based addiction medicine — led by clinicians who are shaping the conversation, not just following it.
